1

Axonics Modulation Tech

#3236

Rank

$3.63B

Marketcap

US United States

Country

Axonics Modulation Tech
Leadership team

Mr. Raymond W. Cohen (CEO & Director)

Mr. Danny L. Dearen (Pres & CFO)

Mr. Rinda K. Sama (Chief Operating Officer)

Products/ Services
Health Diagnostics, Medical, Medical Device
Number of Employees
500 - 1000
Headquarters
Irvine, California, United States
Established
2012
Company Registration
SEC CIK number: 0001603756
Revenue
100M - 500M
Traded as
AXNX
Social Media
Overview
Location
Summary
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
History

Axonics Modulation Technologies Inc. was founded in 2013 to develop a unique implantable device for sacral neuromodulation therapies — using radio frequency delivered through an implantable pulse generator. In 2019, Axonics was the first to receive premarket approval (PMA) from the FDA for a rechargeable implantable neuromodulation device. The approval allowed Axonics to provide its bladder and bowel control offering on a broader scale in the U.S. and worldwide.

Mission
Our mission is to raise the standard of care in neuromodulation therapies by providing superior technology, superior outcomes and superior service.
Vision
Our vision is to make the world a healthier and better place by providing innovations in medicine that can help those who suffer from chronic conditions.
Key Team

Dr. John Woock Ph.D. (Exec. VP, Chief Marketing & Strategy Officer)

Mr. Alfred J. Ford Jr. (Chief Commercial Officer)

Mr. Guangqiang Jiang Ph.D. (Chief Technology Officer)

Mr. Neil Bhalodkar (VP of Investor Relations)

Mr. Michael V. Williamson Esq., J.D. (Sr. VP, Gen. & IP Counsel)

Mr. Aaron Pettit (Gen. Counsel & Chief Compliance Officer)

Dr. Karen L. Noblett M.A.S., M.D. (Chief Medical Officer)

Recognition and Awards
Axonics has been the recipient of many awards and accolades including the MedTech Breakthrough Award for Best Neuromodulation Technology, the Global Healthcare & Medical Device Design Award, and two Prince Albert of Monaco Awards.
References
Axonics Modulation Tech
Leadership team

Mr. Raymond W. Cohen (CEO & Director)

Mr. Danny L. Dearen (Pres & CFO)

Mr. Rinda K. Sama (Chief Operating Officer)

Products/ Services
Health Diagnostics, Medical, Medical Device
Number of Employees
500 - 1000
Headquarters
Irvine, California, United States
Established
2012
Company Registration
SEC CIK number: 0001603756
Revenue
100M - 500M
Traded as
AXNX
Social Media